Politics

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

AP NewsAugust 19, 2026

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanomaapnews.com

Where this sits on TrendsMap

This story hasn’t been tied to a specific state or province yet — it sits in our United States coverage. We hold 2152 politics stories in total, and 231 from AP News.

More Politics More from AP News Open the map

This is a summary of reporting by AP News. Read the full story at the source.

Read full story

Back to home

Predictions (0)

No predictions yet on this story — be the first to start one.

Comments (0)

posting as a guest

Create a free account to comment under your own name and earn Pulse.